CArdioMetabolism and Atherosclerotic PlaqUe progreSsion

Recruiting now

Conditions studied: Coronary Artery Disease, Diabetes Mellitus, Type 2, Dyslipidemias, Obesity, Metabolic Syndrome

In brief

Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.

Key facts

Study ID

NCT05117424

Run by

Ruijin Hospital

People needed

3000

Starts

2017-01-01

Expected to finish

2025-12-31

Last updated by the study team

2024-08-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-80 years
• Established coronary artery disease or metabolic disorders, including:
• Type 2 diabetes diagnosed by one of the following criteria:
• HbA1c >/= 6.5% Fasting plasma glucose >/= 7.0 mmol/l (confirmed) 2h plasma glucose value during OGTT >/= 11.1 mmol/l Already receiving glucose-lowering agents
• Prediabetes
• Obesity
• Chronic kidney disease
• Hyperuricemia
• Dyslipidemia

You may not qualify if…

• Severe liver failure (Child-Pugh grade B to C)
• Severe anemia (hemoglobin < 60g/L)
• Familial hypercholesterolemia
• Active malignant tumor
• Active autoimmune diseases on corticosteroids
• Acute or chronic infection
• Life expectancy < 1 year

Where it is running

• Ruijin Hospital, Shanghai Jiaotong University School of Medicine — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.